FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bradway Robert A  (Last) (First) (Middle)  ONE AMGEN CENTER DRIVE					- A	2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ]  3. Date of Earliest Transaction (Month/Day/Year) 02/18/2021								eck all applic X Directo X Officer below)	cable) or (give title	g Person(s) to Issuer  10% Owner  Other (specify below)  O and President		vner specify
(Street) THOUSA OAKS	C.		91320-17	799	4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	e) X Form f Form f				
(City)	(S		(Zip)															
		Tab	le I - No	n-Deri	vativ	e Se	curit	ies Ac	quired	, Dis	posed o	f, or Be	neficial	y Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				eay/Year) if an		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispo		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	Form:	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ction(s)				
Common Stock 02/			02/18	3/2021	/2021					73,500	A	\$54.69	618,380			D		
Common Stock 02/18/2			3/2021	/2021			F		47,527	D \$235		1 570,853(1)(2)(3)			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date Execution if any (Month/Day/Year) (Month/Day/Year)			Date,	Code (Instr.		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: ly Direct (D) or Indirec (I) (Instr.	Ownership	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Nqso (Right to Buy)	\$54.69	02/18/2021			M			73,500	04/25/20	013	04/25/2021	Common Stock	73,500	\$0	0		D	

## **Explanation of Responses:**

- 1. Non-market exercise of a total of 73,500 stock options expiring April 25, 2021 wherein 47,527 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.
- 2. These shares include the following RSUs granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 3. These shares include 2,382 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

/s/ Robert A. Bradway

02/21/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.